0.4472
price up icon11.60%   0.0465
after-market Handel nachbörslich: .48 0.0328 +7.33%
loading
Schlusskurs vom Vortag:
$0.4007
Offen:
$0.4382
24-Stunden-Volumen:
5.15M
Relative Volume:
2.91
Marktkapitalisierung:
$72.59M
Einnahmen:
$9.10M
Nettoeinkommen (Verlust:
$-82.47M
KGV:
-0.771
EPS:
-0.58
Netto-Cashflow:
$-72.32M
1W Leistung:
+40.58%
1M Leistung:
+6.17%
6M Leistung:
-46.45%
1J Leistung:
-36.99%
1-Tages-Spanne:
Value
$0.43
$0.4777
1-Wochen-Bereich:
Value
$0.3251
$0.4777
52-Wochen-Spanne:
Value
$0.285
$1.07

Vaxart Inc Stock (VXRT) Company Profile

Name
Firmenname
Vaxart Inc
Name
Telefon
(650) 550-3500
Name
Adresse
170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
105
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-14
Name
Neueste SEC-Einreichungen
Name
VXRT's Discussions on Twitter

Vergleichen Sie VXRT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VXRT
Vaxart Inc
0.4472 72.59M 9.10M -82.47M -72.32M -0.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

Vaxart Inc Stock (VXRT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-15 Eingeleitet Oppenheimer Outperform
2021-12-29 Fortgesetzt Jefferies Buy
2021-11-02 Eingeleitet Cantor Fitzgerald Overweight
2021-06-29 Herabstufung B. Riley Securities Buy → Neutral
2021-06-24 Eingeleitet Jefferies Buy
2021-06-11 Eingeleitet Piper Sandler Overweight
2020-08-12 Bestätigt H.C. Wainwright Buy
2020-07-13 Eingeleitet B. Riley FBR Buy
Alle ansehen

Vaxart Inc Aktie (VXRT) Neueste Nachrichten

pulisher
02:43 AM

Vaxart says it can resume next-gen Covid work, will screen participants for oral vaccine trial - Endpoints News

02:43 AM
pulisher
01:11 AM

Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace

01:11 AM
pulisher
11:20 AM

Federal government lifts hold on Peninsula biotech company's vaccine trial - The Business Journals

11:20 AM
pulisher
09:03 AM

Vaxart resumes BARDA-funded trial activities - Investing.com

09:03 AM
pulisher
Apr 22, 2025

Vaccine biotechs say they’ve been told to stop next-gen Covid work under a Biden-era project - Endpoints News

Apr 22, 2025
pulisher
Apr 19, 2025

Biota Pharmaceuticals to Present at Stifel 2015 Healthcare Conference - marketscreener.com

Apr 19, 2025
pulisher
Apr 16, 2025

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23 - GlobeNewswire

Apr 16, 2025
pulisher
Apr 16, 2025

Revolutionary Oral Tablet Vaccines: Vaxart Reveals Latest Breakthrough Data at Major Congress - Stock Titan

Apr 16, 2025
pulisher
Apr 16, 2025

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23 - The Globe and Mail

Apr 16, 2025
pulisher
Apr 11, 2025

Nasal Vaccines Market Top Companies StudyVaxart, Inc, FluGen Inc, Altimmune, Inc, Sinovac Biotech Ltd. - openPR.com

Apr 11, 2025
pulisher
Apr 11, 2025

Proprietary - Vaxart Inc.

Apr 11, 2025
pulisher
Apr 07, 2025

VXRT stock touches 52-week low at $0.31 amid market challenges - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

VXRT stock touches 52-week low at $0.31 amid market challenges By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Mar 30, 2025

RFK Jr. pauses $240 million contract for new ‘oral COVID vaccine’ - Todayville

Mar 30, 2025
pulisher
Mar 28, 2025

VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates - MSN

Mar 28, 2025
pulisher
Mar 27, 2025

Vaxart reports inducement grants under Nasdaq listing rule - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Vaxart Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 27, 2025
pulisher
Mar 27, 2025

Vaxart's Major Talent Investment: 659,500 Share Awards and Key Executive Hire Signals Growth - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

B. Riley Cuts Price Target on Vaxart to $2 From $2.50, Keeps Buy Rating - MarketScreener

Mar 27, 2025
pulisher
Mar 24, 2025

Vaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 24, 2025
pulisher
Mar 22, 2025

Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 22, 2025
pulisher
Mar 21, 2025

Oral - Vaxart Inc.

Mar 21, 2025
pulisher
Mar 21, 2025

Sudden Trump administration order prompts Bay Area company to lay off staff - SFGATE

Mar 21, 2025
pulisher
Mar 21, 2025

Bay Area biotech company lays off staff over sudden Trump admin order - SFGATE

Mar 21, 2025
pulisher
Mar 21, 2025

Vaxart Inc to offer up to $50 mln of common stock -March 21, 2025 at 04:42 pm EDT - MarketScreener

Mar 21, 2025
pulisher
Mar 21, 2025

RFK Jr. paused this Peninsula company's half-billion-dollar vaccine contract, then it cut jobs - The Business Journals

Mar 21, 2025
pulisher
Mar 21, 2025

Vaxart Inc Reports Q4 EPS of -$0.12, Missing Estimates; Revenue at $19.5 Million, Below Expectations - GuruFocus

Mar 21, 2025
pulisher
Mar 21, 2025

Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ... - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments Amid Challenges - GuruFocus.com

Mar 21, 2025
pulisher
Mar 21, 2025

Vaxart Reports 2024 Financial Results and Vaccine Progress - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Vaxart, Inc. Investors of Important Deadline in Securities Class Action – VXRT - Business Wire

Mar 21, 2025
pulisher
Mar 20, 2025

Earnings call transcript: Vaxart Q4 2024 misses EPS but beats revenue - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Vaxart Inc. (VXRT) reports earnings - Quartz

Mar 20, 2025
pulisher
Mar 20, 2025

Vaxart Provides Business Update And Reports Full Year 2024 Financial Results -March 20, 2025 at 04:49 pm EDT - MarketScreener

Mar 20, 2025
pulisher
Mar 20, 2025

Vaxart, Inc. SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewswire

Mar 20, 2025
pulisher
Mar 20, 2025

Vaxart Quadruples Revenue to $28.7M as New Norovirus Vaccine Trial Launches - Stock Titan

Mar 20, 2025
pulisher
Mar 19, 2025

FDA Mid-Month ID Food Recall Safety Updates - ContagionLive

Mar 19, 2025
pulisher
Mar 14, 2025

Pipeline - Vaxart Inc.

Mar 14, 2025
pulisher
Mar 13, 2025

Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20 - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Vaxart, Inc. to Host Conference Call for Business Update and Financial Results on March 20, 2025 - Nasdaq

Mar 13, 2025

Finanzdaten der Vaxart Inc-Aktie (VXRT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
Kapitalisierung:     |  Volumen (24h):